1. Home
  2. NCDL vs WVE Comparison

NCDL vs WVE Comparison

Compare NCDL & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NCDL
  • WVE
  • Stock Information
  • Founded
  • NCDL 2019
  • WVE 2012
  • Country
  • NCDL United States
  • WVE Singapore
  • Employees
  • NCDL N/A
  • WVE N/A
  • Industry
  • NCDL
  • WVE Biotechnology: Pharmaceutical Preparations
  • Sector
  • NCDL
  • WVE Health Care
  • Exchange
  • NCDL NYSE
  • WVE Nasdaq
  • Market Cap
  • NCDL 770.8M
  • WVE 915.6M
  • IPO Year
  • NCDL N/A
  • WVE 2015
  • Fundamental
  • Price
  • NCDL $16.69
  • WVE $6.57
  • Analyst Decision
  • NCDL Hold
  • WVE Strong Buy
  • Analyst Count
  • NCDL 3
  • WVE 12
  • Target Price
  • NCDL $15.75
  • WVE $20.33
  • AVG Volume (30 Days)
  • NCDL 195.6K
  • WVE 948.8K
  • Earning Date
  • NCDL 08-06-2025
  • WVE 08-07-2025
  • Dividend Yield
  • NCDL 10.89%
  • WVE N/A
  • EPS Growth
  • NCDL N/A
  • WVE N/A
  • EPS
  • NCDL N/A
  • WVE N/A
  • Revenue
  • NCDL N/A
  • WVE $104,939,000.00
  • Revenue This Year
  • NCDL N/A
  • WVE N/A
  • Revenue Next Year
  • NCDL N/A
  • WVE $1.94
  • P/E Ratio
  • NCDL N/A
  • WVE N/A
  • Revenue Growth
  • NCDL N/A
  • WVE N/A
  • 52 Week Low
  • NCDL $14.21
  • WVE $4.25
  • 52 Week High
  • NCDL $18.01
  • WVE $16.74
  • Technical
  • Relative Strength Index (RSI)
  • NCDL 67.24
  • WVE 46.68
  • Support Level
  • NCDL $16.16
  • WVE $5.98
  • Resistance Level
  • NCDL $16.85
  • WVE $7.45
  • Average True Range (ATR)
  • NCDL 0.26
  • WVE 0.39
  • MACD
  • NCDL 0.05
  • WVE 0.01
  • Stochastic Oscillator
  • NCDL 83.16
  • WVE 39.73

About NCDL NUVEEN CHURCHILL DIRECT LENDNG CORP

Nuveen Churchill Direct Lending Corp is a specialty finance company focused predominantly on investing in senior secured loans to private equity-owned U.S. middle market companies. It invest in senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: